Current Interstitial Lung Disease and Sarcoidosis Trials
Learn about the active clinical trials underway in the Interstitial Lung Disease Research Unit at KU Medical Center.
CCMK389X2201
A Subject and Investigator Blinded, Randomized, Placebo-controlled, Repeat-dose, Multicenter Study to Investigate Efficacy, Safety, and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis
- Enrollment Status: Active, Open to Enrollment
- Study Type: Interventional (Clinical Trial)
- Intervention/Treatment: CMK389 or Placebo
- Sponsor: Novartis
- PI:  Sahil Pandya, M.D.
- NCT Number: NCT04064242
KIN-1902-2001
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study with Open-label Extension to Assess the Efficacy and Safety of Namilumab in Subjects With Chronic Pulmonary Sarcoidosis.
- Enrollment Status: Active, Open to Enrollment
- Study Type: Interventional (Clinical Trial)
- Intervention/Treatment: Namilumab or Placebo
- Sponsor: Kinevant Sciences, GmBH
- PI: Sahil Pandya, M.D.
- NCT Number: NCT05314517
RIN-PF-301-TETON
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis.
- Enrollment Status: Active, Open to Enrollment
- Study Type: Interventional (Clinical Trial)
- Intervention/Treatment: Inhaled Treprostinil or Placebo
- Sponsor: United Therapeutics
- PI: Sahil Pandya, M.D.
- NCT Number: NCT04708782
RIN-PF-302-TETON OLE
An Open-Label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis.
- Enrollment Status: Active, Open to Enrollment
- Study Type: Interventional (Clinical Trial)
- Intervention/Treatment: Inhaled Treprostinil
- Sponsor: United Therapeutics
- PI: Sahil Pandya, M.D.
- NCT Number: NCT04905693
Precisions
Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial
- Enrollment Status: Active, Open to Enrollment
- Study Type: Interventional (Clinical Trial)
- Intervention/Treatment: N-acetylcysteine (NAC) or Placebo
- PI: Mark Hamblin, M.D.
- NCT Number: NCT04300920
1305-0014
A double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF)
- Enrollment Status: Active, Open to Enrollment
- Study Type: Interventional (Clinical Trial)
- Intervention/Treatment: BI 1015550 or Placebo
- Sponsor: Boehringer Ingelheim
- PI: Mark Hamblin, M.D.
- NCT Number: NCT05321069
FGCL-3019-095
Zephyus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- Enrollment Status: Active, Open to Enrollment
- Study Type: Interventional (Clinical Trial)
- Intervention/Treatment: Pamrevlumab or Placebo
- Sponsor: Fibrogen
- PI: Mark Hamblin, M.D.
- NCT Number: NCT04419558
DWN120882
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of DWN12088 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Enrollment Status: Active, Open to Enrollment
- Study Type: Interventional (Clinical Trial)
- Intervention/Treatment: DWN12088 or Placebo
- Sponsor: Daewoong
- PI: Mark Hamblin, M.D.
- NCT Number: NCT05389215
LYT-100
A Randomized, Double-Blind, Four-Arm Active and Placebo-Controlled Dose-Finding Trial to Evaluate the Efficacy, Tolerability, Safety and Dose Response of LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Enrollment Status: Active, Open to Enrollment
- Study Type: Interventional (Clinical Trial)
- Intervention/Treatment: LYT-100 or Pirfenidone or Placebo
- Sponsor: PureTech
- PI: Mark Hamblin, M.D.
- NCT Number: NCT05321420
HZNP-HZN-825-303
A Phase 2b Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose, Multicenter Trial to Evaluate the Efficiacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis.
- Enrollment Status: Active, Open to Enrollment
- Study Type: Interventional (Clinical Trial)
- Intervention/Treatment: HZN-825 or Placebo
- Sponsor: Horizon
- PI: Sahil Pandya, M.D.
- NCT Number: NCT05032066
CSL312-2002
A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of CSL312 in Subjects With Idiopathic Pulmonary Fibrosis
- Enrollment Status: Active, Open to Enrollment
- Study Type: Interventional (Clinical Trial)
- Intervention/Treatment: CSL312 or Placebo
- Sponsor: CSL Behring
- PI: Mark Hamblin, M.D.
- NCT Number: NCT05130970
1305-0023
A double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
- Enrollment Status: Active, Open to Enrollment
- Study Type: Interventional (Clinical Trial)
- Intervention/Treatment: BI 1015550 or Placebo
- Sponsor: Boehringer Ingelheim
- PI: Mark Hamblin, M.D.
- NCT Number: NCT05321082
ILD-PRO
Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) and Chronic Fibrosing Interstitial Lung Disease With Progressive Phenotype Prospective Outcomes (IPF-PRO/ILD-PRO) Registry
- Enrollment Status: Active, Open to Enrollment
- Study Type: Observational (Patient Registry)
- Sponsor: Boehringer Ingelheim
- PI: Mark Hamblin, M.D.
- NCT Number: NCT01915511
ILDRU Biobank
Interstitial Lung Disease Research Unit (ILDRU) Biobank
- Enrollment Status: Active, Open to Enrollment
- Study Type: Observational (Patient Registry)
- PI: Mark Hamblin, M.D.
- NCT Number: NCT05392881
FGCL-3019-091
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- Enrollment Status: Active, Closed to Enrollment
- Study Type: Interventional (Clinical Trial)
- Intervention/Treatment: Pamrevlumab or Placebo
- Sponsor: Fibrogen
- PI: Mark Hamblin, M.D.
- NCT Number: NCT04419558
GALACTIC-1
GALACTIC-1 -A Randomized, Double-blind, Multicentre, Parallel, Placebo-controlled Phase 2b Study in Subjects With Idiopathic Pulmonary Fibrosis (IPF) Investigating the Efficacy and Safety of GB0139, an Inhaled Galectin-3 Inhibitor Administered Via a Dry Powder Inhaler Over 52 Weeks
- Enrollment Status: Active, Closed to Enrollment
- Study Type: Interventional (Clinical Trial)
- Intervention/Treatment: GB0139 or Placebo
- Sponsor: Galecto
- PI: Mark Hamblin, M.D.
- NCT Number: NCT0383246
IM027-040
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants With Pulmonary Fibrosis
- Enrollment Status: Active, Closed to Enrollment
- Study Type: Interventional (Clinical Trial)
- Intervention/Treatment: BMS-986278 or Placebo
- Sponsor: BMS
- PI: Mark Hamblin, M.D.
- NCT Number: NCT04308681
WA42293 - Starscape
A Phase III Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis
- Enrollment Status: Closed to Enrollment
- Study Type: Interventional (Clinical Trial)
- Intervention/Treatment: PRM-151 or Placebo
- Sponsor: Hoffmann-La Roche
- PI: Mark Hamblin, M.D.
- NCT Number: NCT04552899
WA42294 – Starscape OLE
A Phase III Open-label Extension Study to Evaluate Long-term Safety and Efficacy of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Enrollment Status: Closed to Enrollment
- Study Type: Interventional (Clinical Trial)
- Intervention/Treatment: PRM-151
- Sponsor: Hoffmann-La Roche
- PI: Mark Hamblin, M.D.
- NCT Number: NCT04594707